# Phase 3 Final Audit & Optimization Report

**Audit Date**: July 26, 2026  
**Scope**: Systematic integrity, leakage, capacity, and hyperparameter optimization audit of the 3 frozen expert models (`clinical_v1`, `wearable_v1`, `gut_v1`) prior to Phase 4 Multimodal Fusion.

---

##  EXECUTIVE SUMMARY & GO / NO-GO RECOMMENDATION

| Metric / Audit Check | Clinical Expert (`clinical_v1`) | Wearable Expert (`wearable_v1`) | Gut Expert (`gut_v1`) | Audit Status |
|---|---|---|---|---|
| **Selected Version** | **`clinical_v1` (CatBoost)** | **`wearable_v1` (XGBoost)** | **`gut_v1` (CatBoost)** | **FROZEN & VERIFIED** |
| **Test Set Macro F1** | **0.9595** | **0.8260** | **0.6489** | Matches previous report |
| **Test Set Brier Score**| **0.0094** | **0.0495** | **0.0918** | Well-calibrated |
| **Capacity Status** | Rule Recovery | Feature-Limited (No Overfitting) | Feature-Limited (No Overfitting) | Optimal for modality |
| **Data Leakage Check** | **ZERO LEAKAGE** | **ZERO LEAKAGE** | **ZERO LEAKAGE** | **100% PASSED** |
| **Inference Interface** | **PASSED** | **PASSED** | **PASSED** | **100% PASSED** |

### 🎯 Final Recommendation: **GO FOR PHASE 4 MULTIMODAL FUSION** (Awaiting User Approval)

---

## 🔬 1. CLINICAL EXPERT PERFECT F1 INVESTIGATION: LEAKAGE VS. SYNTHETIC RULE RECOVERY

### Background
During evaluation, the Clinical Expert achieved perfect Test F1 (1.0000) for `Type2_Diabetes`, `Prediabetes`, and `Obesity`. An audit was conducted on `clinical_dataset_generator/disease_rules.py` and SHAP feature attributions to differentiate **Data Leakage** from **Synthetic Rule Recovery**.

### Empirical SHAP Feature Attributions
```txt
• Type2_Diabetes Top Features:
  1. HbA1c (SHAP = 1.9044)
  2. Fasting_Blood_Glucose (SHAP = 1.7391)

• Prediabetes Top Features:
  1. HbA1c (SHAP = 2.7885)
  2. Fasting_Blood_Glucose (SHAP = 1.6231)

• Obesity Top Features:
  1. BMI (SHAP = 4.7167)
```

### Forensic Analysis of `disease_rules.py`
In `clinical_dataset_generator/disease_rules.py`, target labels were generated using standard ADA/WHO clinical diagnostic threshold rules:
- `Type2_Diabetes = (Fasting_Blood_Glucose >= 126) | (HbA1c >= 6.5)`
- `Prediabetes = ((100 <= Fasting_Blood_Glucose <= 125) | (5.7 <= HbA1c <= 6.4)) & (T2D == 0)`
- `Obesity = (BMI >= 30)`

### Audit Conclusion
- **Data Leakage Status**: **NO DATA LEAKAGE.** Target columns (`Type2_Diabetes`, etc.), `Patient_ID`, and `Healthy` are strictly excluded from $X$.
- **Mechanism**: The 1.0000 F1 score represents **LEGITIMATE SYNTHETIC RULE RECOVERY**. CatBoost decision trees easily identified the exact step-function cutoff boundaries present in the synthetic dataset design.
- **NAFLD Exception**: `NAFLD` in `disease_rules.py` uses a probabilistic multi-factor risk score function, which is why Clinical F1 for NAFLD is **0.8109** rather than 1.0000.

---

## 🔒 2. LEAKAGE & SPLIT INTEGRITY VERIFICATION

| Verification Check | Standard / Requirement | Audit Finding | Status |
|---|---|---|---|
| **Predictor Matrix $X$** | Exclude `Patient_ID`, `Healthy`, `Split`, and all 5 target columns | Verified across all 3 datasets | **PASSED ✓** |
| **Preprocessing & Scaling** | Fit strictly on `Split == 'train'` (14,000 patients) | Preprocessor objects fit on Train only | **PASSED ✓** |
| **Calibration & Thresholds** | Fit strictly on `Split == 'val'` (3,000 patients) | Calibrators and threshold tuners used Val fold only | **PASSED ✓** |
| **Master Patient Split** | Identical patient allocation across all 3 datasets | `set(Patient_ID)` 100% identical across all files | **PASSED ✓** |
| **Stratification Workaround** | Modified only composite stratification keys | Target label columns remained 100% untouched | **PASSED ✓** |

---

## 📊 3. CAPACITY ANALYSIS: MODEL-LIMITED VS. DATA-LIMITED

We evaluated Train vs. Validation vs. Test performance for Wearable and Gut models to determine if lower performance is caused by model underfitting/overfitting or intrinsic feature information limits.

| Expert Model | Train Macro F1 | Val Macro F1 | Test Macro F1 | Overfitting Delta (Train - Val) | Diagnosis |
|---|---|---|---|---|---|
| **Wearable Expert** | 0.8312 | 0.8251 | **0.8260** | **+0.0061 (0.6%)** | **DATA / FEATURE-LIMITED** |
| **Gut Expert** | 0.6608 | 0.6509 | **0.6489** | **+0.0099 (1.0%)** | **DATA / FEATURE-LIMITED** |

### Insights:
- Both Wearable and Gut models show **near-zero generalization gap** between Train and Validation/Test sets.
- This proves the models are **NOT overfitting**.
- The lower Macro F1 of Wearable (0.8260) and Gut (0.6489) relative to Clinical (0.9595) is **DATA/FEATURE-LIMITED**:
  - Wearables measure behavioral telemetry (steps, sleep, glucose variability) which correlate moderately with metabolic risk.
  - Gut microbiome taxa provide indirect microbial risk signals.
  - Clinical labs contain direct diagnostic biomarkers.

---

## 🧪 4. HYPERPARAMETER TUNING & ENSEMBLING EXPERIMENTS (TRAIN/VAL ONLY)

We conducted hyperparameter optimization and soft-voting ensemble experiments on the Training and Validation folds ONLY.

### Wearable Expert Experiments (Validation Fold)
| Candidate Model / Strategy | Hyperparameters / Setup | Val Macro F1 | Recommendation |
|---|---|---|---|
| **Existing `wearable_v1` (XGBoost)** | `n_estimators=150, max_depth=5, lr=0.05` | **0.8251** | **KEEP v1** |
| Candidate Deep CatBoost | `iterations=300, depth=6, lr=0.03` | 0.8220 | Reject (-0.0031) |
| Candidate Tuned XGBoost | `n_estimators=300, max_depth=6, lr=0.03` | 0.8251 | Tied (No gain) |
| Candidate Soft Blend Ensemble | XGBoost + CatBoost + LightGBM (1:1:1) | 0.8232 | Reject (-0.0019) |

### Gut Expert Experiments (Validation Fold)
| Candidate Model / Strategy | Hyperparameters / Setup | Val Macro F1 | Recommendation |
|---|---|---|---|
| **Existing `gut_v1` (CatBoost)** | `iterations=150, depth=5, lr=0.05` | **0.6509** | **KEEP v1** |
| Candidate Deep CatBoost | `iterations=300, depth=6, lr=0.03` | 0.6509 | Tied (No gain) |
| Candidate Tuned XGBoost | `n_estimators=300, max_depth=6, lr=0.03` | 0.6497 | Reject (-0.0012) |
| Candidate Soft Blend Ensemble | CatBoost + XGBoost + LightGBM (1:1:1) | 0.6524 | Reject (+0.0015 marginal gain does not justify 3x model complexity) |

### Model Versioning Decision:
- **Clinical Expert**: **KEEP `clinical_v1`**
- **Wearable Expert**: **KEEP `wearable_v1`**
- **Gut Expert**: **KEEP `gut_v1`**

---

## 🔌 5. UNIFIED INFERENCE INTERFACE & TARGET ORDER VERIFICATION

All 3 selected frozen models (`clinical_v1`, `wearable_v1`, `gut_v1`) were verified through `ExpertInferenceEngine`.

### Verified Target Order
`ExpertInferenceEngine` outputs predictions in the exact required target order:
```json
[
  "Type2_Diabetes",
  "Prediabetes",
  "Obesity",
  "Metabolic_Syndrome",
  "NAFLD"
]
```

### Schema & Artifact Verification
- `feature_schema.json`: Frozen & loadable ✓
- `feature_order.json`: Frozen & loadable ✓
- `preprocessor.pkl`: Frozen & loadable ✓
- `calibrator.pkl`: Frozen & loadable ✓
- `thresholds.json`: Frozen & loadable ✓
- `model/estimator.joblib`: Frozen & loadable ✓

---

## 📋 6. FINAL DISEASE METRICS SUMMARY FOR FROZEN EXPERTS

| Target Disease | Clinical F1 (`v1`) | Wearable F1 (`v1`) | Gut F1 (`v1`) | Overall Prevalence | Best Modality |
|---|---|---|---|---|---|
| **Type 2 Diabetes** | **1.0000** | 0.9541 | 0.6479 | 16.70% | Clinical |
| **Prediabetes** | **1.0000** | 0.8517 | 0.5399 | 19.07% | Clinical |
| **Obesity** | **1.0000** | 0.8353 | 0.7502 | 25.67% | Clinical |
| **Metabolic Syndrome** | **0.9867** | 0.7544 | 0.7058 | 20.13% | Clinical |
| **NAFLD** | **0.8109** | 0.7347 | 0.6008 | 13.73% | Clinical |
| **Macro Average** | **0.9595** | **0.8260** | **0.6489** | — | **Clinical** |

---

## ⚠️ 7. KNOWN LIMITATIONS

1. **Synthetic Rule Recovery**: Clinical lab models achieve perfect scores on T2D, Prediabetes, and Obesity due to synthetic generator threshold rules. Real clinical EHR data will contain lab measurement noise, assay variability, and atypical presentations.
2. **Gut Microbiome Prediabetes Sensitivity**: Gut microbiome features alone have lower precision (0.4499) for Prediabetes, reflecting the biological reality that early glycemic shifts do not dramatically alter microbial composition.
3. **Modality Dependency**: Individual expert predictions reflect single-modality views. Multimodal fusion in Phase 4 is required to synthesize these signals into a unified patient risk score.

---

## 🚀 8. EXPLICIT GO / NO-GO RECOMMENDATION FOR PHASE 4

> [!IMPORTANT]
> **GO RECOMMENDATION FOR PHASE 4 MULTIMODAL FUSION**  
> All 3 expert models (`clinical_v1`, `wearable_v1`, `gut_v1`) are leak-free, well-calibrated, fully optimized, reproducibly frozen, and validated on the untouched 3,000-patient test set.  
> The system is ready to proceed to Phase 4 upon user approval.
